About the Speakers

**RDML. Kelly Battese**  
**Chief Executive Officer**  
**Haskell Indian Health Center**

**RDML. Kelly Battese** is the Chief Executive Officer (CEO) for the Haskell Indian Health Center as part of the Indian Health Service (IHS). RDML Battese serves as the United States Public Health Service Chief Professional Officer (CPO) – Pharmacy category. He started his career with the IHS as a clinical pharmacist with the Haskell Indian Health Center in Lawrence, Kansas. His work ethic and leadership skills have transitioned him into several IHS Oklahoma City Area leadership positions. He moved on to serve as the chief pharmacist of the White Cloud Health Station in White Cloud, Kansas and assumed the chief executive officer duties for that facility. Looking to further his knowledge and leadership skills, he transferred to the Claremore Indian Hospital, where he served as the ambulatory care director and later as the hospital’s administrative officer. These positions and experiences led him back to his current position as CEO. RDML Battese was selected as the 12th Pharmacy CPO, providing leadership and direction for the category and consultation with the Surgeon General about policy issues related to the pharmacy profession.

RDML Battese received the 20212 Outstanding Senior Pharmacist of the Year Award for the Oklahoma City Area IHS. In 2019 he received the CEO Award from the IHS Direct Service Tribes Advisory Committee and an IHS Director’s Award. RDML Battese received his Bachelor of Arts in Biology from Tabor College, a Master of Business Administration in health care from Southern Nazarene University, and a Doctorate of Pharmacy from the University of Kansas.

**Raiza M. Beltran, Ph.D.**  
**Postdoctoral Researcher**  
**UCLA Hub for Health Intervention, Policy, and Practice**

**Dr. Raiza M. Beltran** is a postdoctoral researcher for UCLA Hub for Health Intervention, Policy, and Practice (UCLA HHIAPP) at the UCLA Luskin School of Public Affairs. In collaboration with LA LGBT Health Center, she coordinates the P4 (Pharmacists Provision of PrEP/PEP) research project, funded by a National Institute of Health supplemental grant, to engage regional collaborators in Southern California to reduce implementation barriers to pharmacist-delivered PrEP/PEP among key populations. Dr. Beltran also leads the California Pharmacist Study, a statewide initiative that examines the delivery of sexual and reproductive health services in California pharmacies.

Dr. Beltran recently completed a Global HIV Prevention postdoctoral fellowship at the UCLA David Geffen School of Medicine in 2022. Her research interests include examining the structural determinants of low access and use of sexual and reproductive health services among young people in Low- to Middle-Income Countries and diverse minority youth in the United States.
Rachel Browning, M.P.H.
Manager of Health Equity
National Alliance of State and Territorial AIDS Directors

Rachel Browning is a Manager of health equity at the National Alliance of State and Territorial AIDS Directors (NASTAD). Within this role, Rachel works across NASTAD’s seven programmatic teams to implement and support projects focused on advancing equity and dismantling white supremacy. Rachel’s experience as a previous fellow of the Centers for Disease and Prevention’s Public Health Associates Program has helped inform their approach to working with and addressing the unique challenges health departments face when operationalizing equity initiatives. Before working at NASTAD, they served as the education manager for Planned Parenthood of Metropolitan Washington (PPMW). In this capacity, they expanded PPMW’s sexual and reproductive health education initiatives by developing curricula for youth who are neurodiverse, addressing healthcare access for the deaf and hard of hearing communities, and creating community partnerships to promote PrEP education amongst Black cisgender women.

Rachel received their Master of Public Health from Boston University in Global Health and their Bachelor’s degree in social work from the University of Pittsburgh.

Kathy K. Byrd, M.D., M.P.H.
Medical Epidemiologist
Centers for Disease Control and Prevention

Dr. Kathy K Byrd is a Medical Epidemiologist in the HIV Research Branch, Division for HIV Prevention at the Centers for Disease Control and Prevention. Dr. Byrd’s focus is leading the design and conduct of research and implementation of science to increase access to and delivery of HIV care and treatment. In this capacity, Dr. Byrd has led the implementation of several pharmacy-based projects, including a novel HIV care model that integrates community pharmacists with primary HIV medical providers to improve retention in care and adherence to therapy; studies to utilize prescription claims to identify persons living with HIV who fail to fill prescribed antiretroviral treatment and to target these individuals for interventions; online training to prepare pharmacy personnel to communicate effectively with and to serve persons who inject drugs who purchase non-prescription syringes.

Prior to her work in HIV, Dr. Byrd assisted in the development of national Hepatitis B vaccination recommendations and the creation of the first national viral hepatitis action plan. Dr. Byrd has also performed multiple roles in various emergency responses, including the COVID-19, Zika, Ebola, and H1N1 outbreak responses.

Jennifer Cocohoba, Ph.D.
Professor and Vice Chair, Department of Clinical Pharmacy
Co-Vice Dean, Clinical Innovation and Entrepreneurship
University of California, San Francisco School of Pharmacy

Dr. Jennifer Cocohoba is the Professor and Vice Chair for Faculty Development in the Department of Clinical Pharmacy and co-Vice Dean of Clinical Innovation and Entrepreneurship at the University of California, San Francisco School of Pharmacy. At the UCSF Women’s HIV Program, she conducts pharmacotherapy consultations and leads quality assurance initiatives around prescribing. Her research interests focus on pharmacy-based interventions to improve adherence, implementation of pharmacy-based interventions, medication use in people living with HIV, and sex differences in antiretroviral pharmacoepidemiology.
Natalie Crawford, Ph.D.
Associate Professor
Emory University

**Dr. Natalie Crawford** is an Associate Professor in Behavioral, Social, and Health Education Sciences at the Rollins School of Public Health at Emory University. She is also the Co-Director of the Prevention and Implementation Sciences Core in the Center for AIDS Research at Emory. She was trained in social epidemiology and received her PhD in Epidemiology from Columbia University’s Mailman School of Public Health. Dr. Crawford completed her post-doctoral training at the University of Michigan as a Robert Wood Johnson Health and Society Scholar. She is also a graduate of Spelman College, where she trained in Women’s Studies and Biochemistry. Her NIMH-supported research examines the impact of structural interventions in pharmacies on reducing racial inequities in HIV. She is currently advancing the implementation science of HIV prevention services in pharmacies in the Southeast region of the United States.

Alex Dubov, Ph.D.
Associate Professor
Loma Linda University

**Dr. Alex Dubov** is an Associate Professor of Behavioral Science at Loma Linda University and a member of the UCLA Center for HIV Identification, Prevention, and Treatment Services. His work focuses on studying patient preferences to improve the design and implementation of HIV prevention programs. Dr. Dubov’s research interests center around assessing and overcoming barriers to implementing PrEP in health care and community settings. He led an Ending the HIV Epidemic (EHE) study that adapted and implemented a computer-based self-screening intervention to identify Latino Emergency Department patients with SUD-related HIV risks. A similar approach is replicated in his recently awarded three-year study funded by the National Association of Chain Drug Stores Foundation (NACDS). This study aims to improve access to HIV screening, same-day PrEP, and relevant wraparound interventions through community pharmacies, focusing on reaching vulnerable, at-risk minority populations.

E. Jennifer Edelman, M.D., M.H.S., AAHIVS
Associate Professor
Yale University School of Medicine

**Dr. E. Jennifer Edelman** is an Associate Professor of Medicine and Public Health at Yale University School of Medicine. Certified as an internist, HIV specialist, and in Addiction Medicine, she serves as the physician consultant in Addiction Medicine Treatment Program at the Yale New Haven Hospital Nathan Smith HIV Clinic. She routinely treats substance use disorders among individuals with HIV. She is Director of the Yale Center for Interdisciplinary Research on AIDS (CIRA) Clinical and Health Services Research Core, co-Director of Education at the Yale Center for Clinical Investigation, co-Chair of the Veterans Aging Cohort Study (VACS) Opioids Core, and Associate Director of the National Institute on Drug Abuse (NIDA)-funded Research in Addiction Medicine Scholars Program. Funded by NIH, her research over the past 15+ years has focused on understanding and addressing the harms of substance use among individuals with and at substantial risk for HIV. She has experience applying a range of methodologies – including observational, interventional, and implementation science-based approaches – and collaborating with diverse clinical and community-based partners. She enjoys mentoring junior faculty and trainees.
Dr. Walid El-Nahal is an American Association for the Advancement of Science Fellow in the National Institute of Health (NIH) Office of AIDS Research, serving as a member of the Science Team. Dr. El-Nahal is a board-certified Internal Medicine and Infectious Diseases physician. He uses his clinical background in HIV and infectious diseases to support the NIH OAR Senior Science Advisors in advancing critical NIH HIV research priorities. Prior to joining the NIH in August 2022, Dr. El-Nahal completed an Infectious Diseases fellowship at the Johns Hopkins University School of Medicine. In that role, he trained in the clinical care of people with general infectious diseases and those with compromised immunity, including those with organ transplants and HIV. His research interest is understanding how healthcare policies and delivery impact clinical outcomes. His latest work centered on how the widespread adoption of telemedicine during the pandemic has impacted engagement in care for people living with HIV. Dr. El-Nahal is devoted to using his research to inform policy, so his work has been published in peer-reviewed scientific journals and presented to academic conferences and public health agencies. Before joining Johns Hopkins, Dr. El-Nahal trained at the University of Virginia, where he completed medical school, three years of Internal Medicine residency, and a year as a Chief Internal Medicine resident, teaching, training, and supervising junior residents.

Dr. Paul Gaist is Senior Science Advisor in the NIH Office of AIDS Research. He leads the behavioral, social, and population health sciences area of the NIH HIV Research Program and is co-lead for the HIV prevention research priority area. Prior to joining NIH OAR, he has served as an intramural researcher and program director at the National Institute of Mental Health (NIMH); was deputy director for HIV at the former HHS agency, the Alcohol, Drug Abuse, and Mental Health Administration (now SAMHSA); and served as a senior science advisor in the White House Office of National AIDS Policy (ONAP). Dr. Gaist has degrees in psychology and physiology from the University of California, Berkeley as well as a PhD in behavioral science research and health education and an MPH in health policy and management from the Johns Hopkins Bloomberg School of Public Health (JHBSPH). In addition to his work at NIH, he is an adjunct professor, JHBSPH.

Katrease Hale is a public health analyst who works with the Health Department and has fifteen years of fieldwork. She currently lives in Seattle and has recently been working with Health Department to migrate and manage their data systems and then utilize their data to inform program design and improvement intentionally. Katrease is passionate about designing systems to help programs excel and has found working with initiatives like Ending the Epidemic and Data to Care Rx incredibly rewarding.
Jason Hataye, M.D., Ph.D.
Basic Sciences Program
Division of AIDS
National Institute of Allergy and Infectious Diseases

Jason Hataye, MD, PhD is a physician-scientist, at the National Institute of Allergy and Infectious Diseases (NIAID) since 2011. He is board-certified in internal medicine and clinical infectious diseases, and has a research background in virology and cellular immunology. Since 2019, Dr. Hataye has served at the NIAID Division of AIDS in the Basic Sciences Program.

Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP
Vice President and Chief Executive Officer
American Pharmacists Association

Michael D Hogue, PharmD, FAPhA, FNAP, FFIP is Executive Vice President and Chief Executive Officer of the American Pharmacists Association (APhA). Dr. Hogue brings a wealth of experience across pharmacy as he leads APhA as the voice of pharmacy. Dr. Hogue joined APhA after serving as Dean of Pharmacy and Professor of both Pharmacy and Medicine at Loma Linda University in Southern California. He also has a background in pharmacy practice, having worked in preventive medicine, family medicine, and community pharmacy over his nearly 30-year career. Dr. Hogue served as APhA’s president in 2020-21 during the early days of the pandemic. As a public health expert in immunizations, he was the pharmacist representative to the CDC’s Advisory Committee on Immunization Practices and it’s COVID-19 vaccines workgroup, and he headed up Loma Linda University Health’s mass immunization efforts. Under his leadership, over 80,000 doses of COVID-19 vaccines were administered in vulnerable populations. More recently he served on CDC’s Adult RSV vaccine workgroup. APhA advocates for ensuring consumer access to essential pharmacist care services in local communities to sustain the public health infrastructure.

APhA represents the 360,000 pharmacists, 49,000 student pharmacists, over 400,000 pharmacy technicians, and the nation’s pharmaceutical scientists as they ensure appropriate medication use and innovations to prevent and treat illness.

Bishar Jenkins Jr., MPP
Co-leader, Community Mobilization and the Racial Justice and Equity Committees
AIDS United

Bishar Jenkins Jr. is a co-leader for the Community Mobilization and the Racial Justice and Equity Committees at AIDS United. Mr. Jenkins is a health equity practitioner with multisectoral experience, spanning from federal health policy formation on Capitol Hill to national HIV advocacy.

Bishar’s foray into public health began with a summer fellowship at AIDS United, where he outlined recommendations for infusing racial and gender justice frameworks into the organization’s grantmaking initiatives. In the intervening years after his summer fellowship with AIDS United, Bishar served as a Congressional Black Caucus Foundation Health Fellow. In this capacity, he served as a health policy staffer in Congresswoman Frederica S. Wilson’s (D-FL) office and as a fellow at the CDC’s Division of HIV Prevention. Notably, Bishar oversaw and coordinated the launch of AIDS United and its Public Policy Council’s long-awaited Racial Justice Index, the first nationwide survey of the HIV workforce on racial justice and Blackness.

Bishar earned a BA in Political Science from Rutgers University and an MPP from Brandeis University.
Jeremiah Johnson, M.P.H.
Executive Director
PrEP4All

Jeremiah Johnson has been PrEP4All’s Executive Director since November 2022. Since joining PrEP4All in January 2022, he has led the organization’s fight for a National PrEP Program, building on a proposal for a novel approach to PrEP financing and delivery he co-drafted in 2021 in partnership with Johns Hopkins University. Jeremiah’s career in HIV/AIDS advocacy has grown from his personal experiences with the virus. Jeremiah was 25 when he was diagnosed with HIV while serving as a Peace Corps volunteer in Ukraine. When he was dismissed after testing positive, he worked with the ACLU to overturn Peace Corps’ policy. Following his dismissal, Jeremiah pursued further advocacy in the field of HIV/AIDS, working as a case manager and prevention specialist in rural Colorado before deciding to pursue a Masters in Public Health at Columbia University. Jeremiah was honored by POZ magazine as one of the top 100 HIV/AIDS activists in the United States in 2010.

In 2013, Jeremiah joined Treatment Action Group, eventually becoming Director of the HIV Project from 2018 to 2021. As part of TAG, he worked to promote universal access to treatment and comprehensive HIV prevention, better and more ethical research, and prevention strategies that take into account the true complexity of HIV in the United States. In 2015, he and PrEP4All cofounder James Krellenstein led advocacy that secured millions in funding for New York City’s sexual health and wellness clinics. In 2019, he advocated for the convening of an FDA panel to review the evidence base for Descovy as PrEP, successfully calling for more research to be done on F/TAF in cisgender women and transgender men.

Mariano Kanamori, Ph.D.
Associate Professor at the University of Miami Miller School of Medicine
University of Miami Miller School of Medicine

Dr. Mariano Kanamori is a Latinx prevention scientist with over 20 years of experience designing and implementing studies that reduce HIV and drug use in underserved populations. He emphasizes incorporating implementation science, community-based participatory research, and social network analysis into his projects. Dr. Kanamori received his PhD in Epidemiology from The University of Maryland School of Public Health. Dr. Kanamori is an Associate Professor at the University of Miami Miller School of Medicine, Division of Prevention Science and Community Health. Dr. Kanamori has implemented an Ending the HIV Epidemic (EHE) project with CVS Health and the community organization Latinos Salud. This EHE project was the first biomedical HIV implementation science program to use four network-based strategies (pharmacy, social, parks, and radio), each designed to reach large numbers of Latinx. Dr. Kanamori is currently conducting transformative bio-behavioral HIV prevention research using social network approaches he has developed. One project, FINISHING HIV R01 (NIAIDS R01AI169643), is a randomized controlled trial of an implementation science strategy that bundles social network support and one-stop-shop PrEP services to improve PrEP (pre-exposure prophylaxis) initiation of Latinx men who have sex with men. In this study, Dr. Kanamori collaborates with CVS Health and Latinos Salud. The combination of social network support, one-stop-shop PrEP services, and community and national pharmacy chain partners is a promising model that can be replicated in other EHE priority areas nationwide.
Bill G. Kapogiannis, M.D.
Acting Associate Director, AIDS Research
Acting Director, Office of AIDS Research, NIH

Dr. Bill G. Kapogiannis is a Fellow of the Infectious Diseases Society of America. In addition, he serves as Acting Associate Director of AIDS Research and Acting Director of the Office of AIDS Research (OAR) at the National Institutes of Health (NIH). In this role, he leads NIH OAR in coordinating the NIH HIV research agenda to end the HIV pandemic and improve the health of people with HIV. An NIH leader in HIV research for nearly 18 years, Dr. Kapogiannis, joined NIH OAR from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, where he led several research programs for HIV treatment and management in children and adolescents.

Donald Klepser, Ph.D.
Professor, Pharmacy Practice and Science and Associate Dean, Academic Affairs
University of Nebraska Medical Center, College of Pharmacy

Dr. Donald Klepser is Professor of Pharmacy Practice and Science and Associate Dean for Academic Affairs at the University of Nebraska Medical Center, College of Pharmacy. He has a PhD in Pharmaceutical Socioeconomics from the University of Iowa, an MBA from the University of Minnesota, and a Bachelor's degree in Communications from the University of Michigan. He has studied POC testing in pharmacies for the past 13 years. He has been the primary investigator on grants to develop pharmacy practice models for screening and managing HIV in the pharmacy setting. He has also worked with pharmacies to develop pharmacy-based PrEP programs.

Angela Lee-Winn, Ph.D.
Social & Behavioral Scientist Administrator
Division of Epidemiology, Services, and Prevention Research (DESPR)
National Institute on Drug Abuse (NIDA)

Dr. Angela Lee-Winn (she/her/hers) is a program official in the Division of Epidemiology, Services, and Prevention Research at the National Institutes on Drug Abuse. Dr. Lee-Winn’s work spans both the Prevention Research Branch and Services Research Branch. In the Prevention Research Branch, her work focus on HIV prevention among people who use drugs, with a special emphasis on women & girls. In the Services Research Branch, her responsibilities include international grants, particularly those focused on HIV research and HIV training grants. She is a prevention scientist and psychiatric epidemiologist by training. Dr. Lee-Winn has interests in dissemination and implementation (D&I) science, including multi-level, systematic adaptation, implementation, and evaluation of sustainable, evidence-based strategies across HIV and substance use cascade of care.
Jenny Liu, Ph.D., MPP  
Associate Professor of Health Economics  
University of California, San Francisco

Dr. Jenny Liu is an Associate Professor of Health Economics in the Department of Social and Behavioral Sciences at the University of California, San Francisco. She aims to identify innovative, cost-effective, and scalable interventions for vulnerable populations using diverse approaches that marry empathy with behavioral sciences and rigorous mixed-methods evaluations. Her recent work has increasingly focused on designing holistic structural and behavioral person-centered interventions delivered through non-traditional channels (e.g., community health workers, e-commerce and digital interfaces, private community drug shops, and pharmacies, community-based distributors) to reach adolescent girls and young women, sex workers, and rural households. Across study sites in sub-Saharan Africa, she leads several studies that leverage, test, and prepare these delivery platforms for scaling next-generation sexual and reproductive health technologies—self-injectable subcutaneous depot medroxyprogesterone acetate (DMPA-SC), HIV self-testing and pre-exposure prophylaxis—designed to empower self-care and overcome access barriers in resource-poor settings. Prior work includes studies on malaria and child health. She advises NGOs, donors, the World Health Organization, the World Bank, and Ministries of Health.

Stephen Massey  
Managing Director, Health Action Alliance/U.S. Business Action to End HIV  
Co-founder, Meteorite

Stephen Massey is a social entrepreneur and co-founder of Meteorite, an impact agency that builds large-scale private-sector coalitions to strengthen our democracy and improve health and wellness in communities nationwide. In this role, he serves as Managing Director of the Health Action Alliance, a unique partnership between leading business, communications, and public health organizations to help employers respond to emerging health challenges, improve health equity and help rebuild public health. In 2022, HAA launched U.S. Business Action to End HIV, a growing coalition of businesses committed to accelerating progress to end HIV in the U.S. by 2030.

Over the past two decades, Stephen has built Emmy and Peabody Award-winning campaigns on a wide range of social issues, and he has cultivated initiatives with major foundations, media organizations, government agencies, and Fortune 500 companies. Prior to launching Meteorite, Stephen helped lead the Global Media AIDS Initiative, a joint effort between the United Nations and the Kaiser Family Foundation that mobilized more than 300 of the world’s leading media companies in response to AIDS. In 2002, Stephen co-founded Transatlantic Partners Against AIDS, a non-profit policy organization based in Moscow that brought together business and civil society to raise awareness, fight stigma and combat the surging AIDS crisis in Russia and Ukraine.

A first-generation Cuban American, Stephen served as a White House National Security Fellow in the Clinton Administration and studied international development and economics at Georgetown, Columbia, and Oxford Universities.
Katrina Ortblad, Sc.D.
Implementation Scientist and Assistant Professor
Fred Hutchinson Cancer Research Center in the Public Health Sciences Division
Affiliate Assistant Professor, University of Washington

Dr. Katrina Ortblad is an implementation scientist and Assistant Professor at the Fred Hutchinson Cancer Research Center in the Public Health Sciences Division and an Affiliate Assistant Professor at the University of Washington in the Department of Global Health. Her research seeks to improve equity in health access with differentiated models of HIV service delivery in high-prevalence settings. Her ongoing projects, all in Kenya, include a randomized trial that explores the use of HIV self-testing (HIVST) to decrease the number of PrEP clinic visits, a study to design and test a novel model of pharmacy-based PrEP delivery, and a study to develop and test a peer PrEP referral + HIVST delivery model to increase PrEP uptake and continuation among young women. She uses diverse research methods across the fields of epidemiology, economics, public policy, psychology, and implementation science.

Tam Phan, PharmD, AAHIVP
Assistant Professor of Clinical Pharmacy
USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences

Dr. Tam Phan is an Assistant Professor of clinical pharmacy (clinician-educator) at USC Mann and the Clinical Pharmacy Program Coordinator at the Los Angeles LGBT Center. His clinical practice site focuses on delivering specialized patient-centered care for LGBT+ people and people living with HIV. He teaches and is involved in curriculum development for the school’s undergraduate programs, including the Pharmacology and Drug Development major and the minor in Science and Management of Biomedical Therapeutics.

Phan completed postgraduate residency training in community pharmacy practice at USC Mann, receiving a teaching certificate and his Doctor of Pharmacy. His residency training included providing clinical pharmacy services in the outpatient setting and an extended experience in HIV care at LAC+USC Maternal Child and Adolescent Adult clinic. His practice interests include primary care, HIV/AIDS care, LGBTQ+ care, comprehensive medication management, community-based pharmacy practice and operations, integrative medicine, travel health, immunizations, community health, and disease screening, management, and prevention.

Glen Pietrandoni, R.Ph., AAHIVP
Chief Advocacy Officer
Avita Care Solutions

Glen Pietrandoni is Chief Advocacy Officer at Avita Care Solutions, an award-winning pharmacy leader, passionate 340B program advocate, and internationally respected HIV and LGBTQ+ activist. He’s deeply engaged in Avita’s mission to advocate for health equity and the 340B Drug Pricing program. He works to bring together stakeholders from the pharmaceutical industry and patient advocacy arenas. Through webinars, conferences, Avita’s thought leadership blog series “The Take,” and the organization’s engagement with multiple community and trade associations, Glen leads Avita’s educational and awareness efforts and acts as a voice for its covered entity partners and patients. He continually fights for continued access to the 340B program and advances stigma-free HIV, PrEP, LGBTQ+, and sexual wellness care for underserved patient populations. Glen recently received Pharmacy Times’ Lifetime Leadership honor at the Next-Generation Pharmacist Awards. He serves on the Board of Pharmacy for the State of Illinois, was formerly chairman of the Board of Trustees of AIDS United, and sits on the board of Community Voices for 340B (CV340B). He has earned the American Academy of HIV Medicine and Apexus 340B certifications.
Jillian Pintye (she/her), Ph.D., R.N., M.P.H.  
Nurse-Scientist and Associate Professor  
University of Washington

Dr. Jillian Pintye is a nurse scientist and Associate Professor in the Department of Biobehavioral Nursing and Health Informatics at the University of Washington. She is also affiliated with the Global Center for Integrated Health of Women, Adolescents, and Children (Global WACH) in the University of Washington’s Department of Global Health. She is a Research Associate at the Botswana Harvard Partnership. Jillian’s research focuses on HIV and STI prevention and treatment, particularly within maternal-child health and family planning settings. She is engaged in a suite of studies related to pre-exposure prophylaxis (PrEP) for HIV prevention among young cisgender women and pregnant populations in Kenya, including both clinical epidemiology and implementation science studies.

Aleata Postell  
Lead, Specialty Pharmacy Business Development and Specialty Central Operations  
Walmart

Aleata Postell is an accomplished Senior Leader in Pharmacy Operations and Service Delivery for notable organizations, including Aetna, Prime Therapeutics, AllianceRx Walgreens Prime, and Walmart.

Aleata has over 15 years of specialty leadership experience and currently leads the Specialty Pharmacy Business Development and Specialty Central Operations for Walmart. In this role, Aleata is responsible for developing Walmart’s retail and central operations specialty strategy. She also leads working with cross-functional teams to drive and execute Walmart’s goals for specialty pharmacy, aligning with Walmart’s vision for delivering best-in-class healthcare to all. Prior to coming to Walmart, Aleata served as the Vice President of Client Service Delivery, Prescriber Engagement, Pharmacy Implementation, and Integration for AllianceRx Walgreens Prime. She is an expert at building and expanding all aspects of pharmacy programs, driving operational excellence, and developing pharmacy strategies that improve the patient, prescriber, and client experience.

Outside of Aleata excelling in her corporate roles, she has a deep passion for developing and promoting underprivileged youth and underrepresented communities. Her servitude is evident in her many years of mentorship serving high school juniors and seniors, college students, athletes, and minorities trying to pursue higher education. She ensures they get the proper training and experience to foster their creativity, maturity, and skills to close the gap and obtain gainful employment as young professionals. Not only has she been successful in her community and personal roles, but she has a strong desire for increasing diversity and inclusion in the workplace, which she has proven by taking on mentees to groom them for leadership roles. Aleata has also served as an Executive Chair on steering committees and client advisory boards and currently holds a position on the Board for the National Association of Specialty Pharmacy. She holds a Bachelor of Science in Legal Studies and has credentials with McKinsey’s and Company’s Leadership program.
Dima Mazen Qato, Ph.D., PharmD, M.P.H.
Hygeia Centennial Chair, Associate Professor, and Director
University of Southern California School of Pharmacy

Dr. Dima Mazen Qato serves as the Hygeia Centennial Chair and Associate Professor (with tenure) and Director of the Program on Medicines and Public Health at the University of Southern California School of Pharmacy and is a Senior Fellow with the USC Leonard D. Schaeffer Center for Health Policy and Economics.

Prior to joining USC, Dr. Qato was an Associate Professor in the Department of Pharmacy Systems, Outcomes, and Policy at the University of Illinois at Chicago College of Pharmacy (2012-2020). She also serves as a National Academy of Medicine Pharmacy Fellow for 2018-2020. Dr. Qato received her PharmD from UIC, an MPH from the Johns Hopkins School of Public Health, and a PhD in Public Health from the University of Illinois School of Public Health.

Dr. Qato’s research focuses on access and safe use of medicines and pharmaceutical policy both in the U.S. and globally and seeks to better understand why medications are used or not used and how they can and should be used in the population to promote equity, longevity, and good health. Dr. Qato’s research utilizes population-based methods to better understand the underlying mechanisms responsible for the use, underuse, and unsafe use of medications, how these patterns may influence health outcomes and health disparities, and what can be done from a community and policy perspective to address these growing public health problems.

Dianne Rausch, Ph.D.
Director, Division of AIDS Research
National Institute of Mental Health

Dr. Dianne Rausch is the Director of the Division of AIDS Research at NIMH, a component of NIH. In this role, she manages a research portfolio encompassing a broad range of studies with the overarching goal of reducing the incidence of HIV/AIDS worldwide and decreasing the burden of living with HIV/AIDS. To this end, the Division supports research that includes basic and clinical neuroscience to better understand and alleviate the consequences of HIV infection of the central nervous system (CNS) and basic and applied behavioral science to prevent new HIV acquisitions and limit morbidity and mortality among those living with HIV. The Division prioritizes interdisciplinary research across multiple populations, including racial and ethnic minorities, over the lifespan. Dr. Rausch received her BS in Biology from the University of Oregon and her PhD in Cell and Molecular Biology from Northwestern University. Prior to her work in the Division, she spent ten years in the NIMH Intramural Program studying HIV toxicity in the CNS and its impact on neural function.

Sarah Read, M.D.
Deputy Director, Division of AIDS
National Institute of Allergy and Infectious Diseases

Sarah Read, MD, serves as Deputy Director of the Division of AIDS (DAIDS) at the National Institute of Allergy and Infectious Diseases (NIAID). The division supports a global HIV/AIDS research portfolio in the areas of 1) fundamental basic laboratory research, 2) discovery and development of therapies for HIV infection, related co-infections, and non-infectious co-morbidities, and the complications associated with treated HIV disease, and 3) discovery and development of vaccines and other prevention strategies through basic research and clinical trials. Previously, Dr. Read served as Director of the Therapeutics Research Program in DAIDS. Prior to joining DAIDS, she was an Associate Clinical Investigator in the Laboratory of Immunoregulation at NIAID where her research focused on immune activation and inflammation in treated HIV infection as well as on immune based therapies for HIV.
Dr. David Serota is an associate professor of medicine at the University of Miami Miller School of Medicine. He is an infectious disease and addiction medicine physician with clinical, research, and educational work at the intersection of ID and substance use. He is a “harm reduction” advocate, and much of his work has focused on reducing stigma toward people who inject drugs, improving access to addiction treatment, and implementing harm reduction interventions. He helps run a low-barrier buprenorphine program through Miami’s syringe exchange program and has published research on pharmacy-related barriers to receipt of buprenorphine to treat opioid use disorder in Florida.

Dr. Sandra Springer is a Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale University School of Medicine. She is also an attending infectious disease physician at the Veterans Administration Connecticut Healthcare System and directs the VA Newington, CT Infectious Disease Clinic. She received an A.B. from Harvard University and an MD from the University of Massachusetts Medical School. She completed her Internal Medicine Residency and Infectious Diseases Fellowship at Yale School of Medicine. She has significant clinical and research experience with people living with and at risk of HIV and substance use disorders (SUD), including within the criminal justice system. She is the Director of InSTRIDE (Integrating Substance Use Treatment Research with Infectious Disease Treatment for Everyone) at the Yale School of Medicine, where she and her team conduct clinical research on the integration of SUD and Infectious Disease/HIV prevention and treatments. In particular, she has focused on evaluating medication treatments for opioid and alcohol use disorders to improve substance use and ID/HIV treatment. She is a Principal Investigator of 6 NIH awards and 1 VA Cooperative Studies award. In addition, Dr. Springer was awarded an Avant-Garde Award by NIDA in June of 2022 to evaluate a cutting-edge mobile innovative program to provide medication treatment of opioid use disorder integrated with PrEP/ HIV treatment for people who use drugs wherever they live with mobile pharmacies, telehealth, and community health workers. She has presented her research numerous times, both nationally and internationally, and has published over 100 manuscripts and book chapters.

Dr. Stacy Sterling is a Research Scientist and Co-Director of the Center for Addiction and Mental Health Research Kaiser Permanente Northern California (KPNC) Division of Research. She is also an Associate Adjunct Professor for the UCSF Department of Psychiatry and Behavioral Sciences and an Associate Professor for the Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine. She received her doctoral training at the University of North Carolina, Chapel Hill, Gillings School of Global Public Health, and Master’s degrees in Public Health and Social Welfare at the University of California, Berkeley. Her research focuses on developing health policies and interventions to increase treatment access to health, substance abuse, and mental health services and improve outcomes for vulnerable populations. She is the Principal Investigator of several NIH- and foundation-supported studies focused on the identification and treatment of alcohol, drug, and other behavioral health problems, in adult and pediatric primary care and other non-specialty treatment settings and the implementation, sustainment, and health outcomes related to alcohol screening, brief intervention, and treatment in primary care.
Dr. Michael J. Stirratt
Senior Behavioral Scientist and HIV Adherence Program Officer
Division of AIDS Research
National Institute of Mental Health

Dr. Michael J. Stirratt is a Senior Behavioral Scientist and Program Officer the NIMH Division of AIDS Research, where he leads a portfolio of Federal research grants addressing HIV treatment and prevention adherence. Dr. Stirratt has worked in HIV behavioral research over 25 years. He has led research initiatives to improve monitoring and support for antiretroviral medication adherence among people with HIV, as well as initiatives to strengthen delivery and use of HIV pre-exposure prophylaxis (PrEP). Dr. Stirratt participates in scientific working groups or protocols in multiple NIH HIV Research Networks, including the ACTG, HPTN, and HVTN. He co-Chairs the NIH Adherence Network, an internal scientific interest group which provides leadership and vision for adherence research at NIH.

Elyse Tung, PharmD, BCACP
Pharmacist and Director of Clinical Services
Kelley-Ross Pharmacy

Dr. Elyse Tung is a pharmacist and Director of Clinical Services at Kelley-Ross Pharmacy. She implements and oversees clinical programs at Kelley-Ross Pharmacy, including the travel clinic, immunizations, and long-acting injectables. The most recent and relevant services include the first HIV PrEP clinic managed by a pharmacist in a community pharmacy setting in 2015. In 2020 the same model was used to develop a pharmacist-managed Hepatitis C treatment clinic in a community pharmacy setting. She is also a Clinical Assistant Professor at the University of Washington School of Pharmacy. Before that, she completed her pharmacy practice residency at Swedish Medical Center in Seattle and worked at Overlake Senior Care Center in Bellevue, WA.

Taylor Ward, PharmD, BCPS, BCIDP
Clinical Pharmacy Specialist
Boston Medical Center in the Center for Infectious Diseases

Dr. Taylor Ward is a clinical pharmacy specialist at Boston Medical Center in the Center for Infectious Diseases clinic, caring for persons living with HIV. She completed her PGY1 pharmacy practice residency at Cone Health in Greensboro, NC, and her PGY2 in Infectious Diseases at Cone Health. She works collaboratively with providers in clinics to implement new services and provide clinical management for patients.

Kenric B. Ware, PharmD, M.B.A., AAHIVP
Clinical Associate Professor of Pharmacy Practice
Mercer University College of Pharmacy

Dr. Kenric B. Ware is a Clinical Associate Professor of Pharmacy Practice at Mercer University College of Pharmacy in Atlanta, GA. Kenric serves on the board of directors for the Joseph H. Neal Health Collaborative based in Columbia, SC. Kenric is also a member of the South Carolina HIV Planning Council. Regionally, Kenric contributes as a member of the Southeastern AIDS Education and Training Center Advisory Committee. Nationally, Kenric is a part of the American Academy of HIV Medicine’s Southeastern Regional Steering Committee and Public Policy Committee.
Captain Paul J. Weidle, PharmD  
Senior Advisor, Office of the Chief Medical Officer  
Division of HIV Prevention, CDC  

Captain Paul J. Weidle is a Senior Advisor in the Office of the Chief Medical Officer of the Division of HIV Prevention at the Centers for Disease Control and Prevention (CDC). Since 2019, he has served in a leadership role for CDC’s Ending the HIV Epidemic planning, design, promotion, and implementation. He currently provides operational oversight and leadership to CDC’s Ending the HIV Epidemic Pillar Workgroups for Diagnose, Treat, Prevent, and Respond. During his career at CDC, Captain Weidle has conducted research, implemented programs, and published more than 100 peer-reviewed papers, including publications on pharmacist delivery of HIV prevention and care services. CAPT Weidle received a Doctor of Pharmacy degree from the University of Maryland at Baltimore in 1986 and a Master of Public Health from Johns Hopkins School of Hygiene and Public Health in 1997. He joined the CDC as an Epidemic Intelligence Service Officer in 1997 and has spent most of his CDC career in the Division of HIV Prevention.

John Wigneswaran, M.D.  
Chief Medical Officer  
Walmart Healthcare Research Institute  

Dr. John Wigneswaran (Dr. Wig), is Walmart’s Chief Medical Officer leading safety, quality, and training, the Walmart Healthcare Research Institute, clinical program development, innovation, and medical affairs.

He joined Walmart in 2021 from Cigna, where he served as Chief Medical Officer for Express Scripts. Before that, he held various roles in the pharmaceutical, medical device, PBM, and healthcare services industries, including DaVita, Fresenius Medical Care, Gambro, Nephroceuticals, and Johnson & Johnson. He has over a decade of clinical experience as a practicing nephrologist and is a renal fellowship preceptor in the Division of Nephrology at Rhode Island Hospital/Brown University.

Dr. Wig completed his undergraduate studies at Cornell University, attended medical school at the Tufts University School of Medicine, and completed his nephrology fellowship at New York-Presbyterian/Weil Cornell Medical Center and internal medicine residency at Rhode Island Hospital/Brown University. He received his MBA from the Massachusetts Institute of Technology Sloan School of Management. Dr, Wig currently resides in Boston, MA.

Heidi Wood, PharmD, BCPS, AAHIVP  
Clinical Pharmacy Specialist  
Iowa TelePrEP  

Heid Wood is a Clinical Pharmacy Specialist with Iowa TelePrEP, an HIV PrEP telehealth program made possible through a partnership between the University of Iowa Health Care and the Iowa Department of Health and Human Services. Prior to this role, she worked in the University of Iowa Health Care’s Virology and Hepatology Clinics, providing care to people living with HIV and viral hepatitis.

Heidi will complete the MAS program in Population Health Management through Johns Hopkins University in 2024. She plans to combine knowledge gained through this degree with her expertise in designing clinical services to focus on enhancing the health-related quality of life in populations she works with.